Cisplatin and Nano-particle Formulations of Cisplatin for Cancer Therapy: A Review
Popsy Raj, Bharat Lal, Manoj Gadewar, Anita Singh, G. K. Prashanth
Journal of Pharmaceutical Research International · pp. 34–49 · Published 22 Feb 2022
10.9734/jpri/2022/v34i14A35636Abstract
Cisplatin (cis-(diammine)dichloridoplatinum(II)) is the first platinum-based compound approved by the United States Food and Drug Administration (FDA) (U.S.). This is a first-line chemotherapeutic treatment used alone or combined with other anticancer drugs to treat a broad spectrum of malignancies, with cisplatin-based nano-formulations currently in clinical studies. Cisplatin has several drawbacks, including low aqueous solubility, drug resistance, and toxicity, all of which can be addressed by encapsulating the drug in Nemours nanocarriers. The various nano-delivery technologies developed for Cisplatin are covered in vast literature from different electronic databases. This review focuses on comparative findings over the recent advancements, developments, innovations, and updated literature for various CDDP nano-carrier systems.
Cited by 8
Iosif-Aliodor Timofticiuc, Alex-Gabriel Grigore, Elena-Teodora Tomescu · Pharmaceutics · 2025
Chitrali Talele, Dipali Talele, Niyati Shah · Drug Delivery Letters · 2025
Astha Sharma, Jiachen Yan, Prakrit Siwakoti · Nano TransMed · 2024
Showing 3 of 8 known citations — external sources report more than can currently be individually listed.
Related research
- Does Pain Adversely Affect the Quality of Life in Hospitalized Cancer Patients? — shares topic coverage
- Complementary Medicine Intervention in Breast Cancer Patients with Pain — shares topic coverage
- Use of Performance Status Score for Cytotoxic Chemotherapy among Surgeons in a Tertiary Hospital, Southern Nigeria — shares topic coverage
- Breast Self Examination and Cancer Awareness among Female Staff in Federal Medical Center, Yenagoa, Bayelsa State (Knowledge and Practice) — shares topic coverage
- Assessment of Cancer Risk from Fluorscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar — shares topic coverage
Article metrics
Real usage data collected on this platform.
13
Page views
0
PDF downloads
1
Outbound clicks
8
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.